When it comes to the supply chain, business can be risky. A seminal survey of companies in...
The development of new chemistry-based products for life science markets requires the expertise...
When it comes to the inspection of cleaned equipment of pharmaceutical manufacturing equipment,...
SAFC, a global company that supplies a multitude of services to the biopharm/pharmaceutical industry has recently opened a new Dry Powder Media (DPM ) manufacturing facility in Irvine, Scotland to complement their Lenexa, KS DPM facility. By doing so SAFC has shown their commitment to their customers and this growing segment of the pharmaceutical industry.
Due to the special containment requirements for manufacturing highly potent active pharmaceutical ingredients and cytotoxic drugs, we have seen many CMO’s invest in building additional capacity in this area. While there are tremendous benefits and a strong promise with these types of products there are also considerable challenges and risks associated with their production, especially in a multiproduct CMO environment.
As serialization becomes an ever more important part of the pharmaceutical industry and the FDA's track & trace deadlines loom in the distance, we sat down with Kelly Ng, the Healthcare division's Product Manage at Epson, to talk about the state of track and trace/serialization technology, whether the industry is ready for the new requirements and how companies can make sure that they will make the upcoming deadlines.
Mention the terms ‘cell therapy’ or ‘regenerative medicine’ and many in the general public are still confused as to what those terms actually mean. But those in the know understand that cell therapy is a growing and thriving industry, with great potential to change the face of modern healthcare.
During the last quarter of 2013, PwC surveyed more than 1,300 business leaders across 68 countries around the world, and the pharmaceutical and life sciences sector was well represented. The results showed a number of positives for all businesses, notably a leap in CEOs’ confidence in the global economy. But PLS leaders are cautious as to whether this will translate into better prospects for their own companies.
Facing unprecedented economic pressures, pharmaceutical manufacturing companies are continuously looking to improve on the quality of their products and the productivity of their processes. Multi-physics numerical simulation is emerging as game-changing technology to help step up efficiency, enhance quality, and shorten time-to-market through virtual prototyping and optimization.
A characteristic of good science is good data. Quality data are arguably more important today than ever before. Data are used to develop products and processes, control manufacturing processes and improve products and processes. Quality data also reduces the risk of poor process performance and defective pharmaceuticals reaching patients.
Balancing Demand with Supply: Thermoplastic Elastomers Help Satisfy Growing Global Need for Pharma Packaging and DevicesMay 6, 2014 3:38 pm | by John Voyce, PolyOne GLS Thermoplastic Elastomers | Comments
Many companies are looking for new ways to build faster throughput and greater scalability into their supply chains while optimizing costs. One proven approach is replacing traditional vulcanized rubber materials with thermoplastic elastomers (TPEs).
Outsourcing continues to be an integral part of biopharmaceutical manufacturing, and facilities are outsourcing activities today at heightened levels. As a result, the contract manufacturing organization (CMO) community has seen an expansion of opportunities, leading to increased competition. In this science and technology-driven environment, how can CMOs separate themselves from the pack?
PCI, Inc. a contract manufacturing and research organization based in Newburyport, MA that develops and manufactures NCEs, generic APIs and fine chemicals has grown from a small start-up to a company that can now take a product all the way from development to commercial production in a smooth and seamless process for its clients.
When it comes to coating tablets there are musts that really count and then there are the other things.
It seems simple enough . . . when planning a new laboratory facility, ensure that there is adequate storage space and that it is located in the right place and arranged to accommodate access based upon frequency of use. And yet, much can go wrong…and often does.
Today’s biopharmaceutical manufacturers face a wide range of challenges. The regulatory landscape has become more scrutinizing as it has grown increasingly complex. Supply chains have grown into supply webs, with intricate logistics and compliance issues. Competition — and pressure to cut costs — keeps climbing along with the rate of mergers and acquisitions.
When developing a clean room program, it is important to make sure that the plan meets all regulatory requirements mandated by agencies such as the Institute of Environmental Sciences and Technology (IEST) and the International Organization for Standardization (ISO).
No two packaging projects are alike and in order to make it all work and to keep everything on track and everyone happy you need to have a flexible, responsive and quality-driven organizations. Reed-Lane has deftly combined these qualities along with recent investments to create a truly flexible contract packaging operation.